Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oncolytics Biotech (ONCY)
NASDAQ:ONCY
RESEARCH TOOLSreports
Holding ONCY?
Track your performance easily
ONCY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.85 - $2.42
Previous Close$0.95
Volume171.31K
Average Volume (3M)180.00K
Market Cap
$73.06M
Enterprise Value$47.42M
Total Cash (Recent Filing)C$34.91M
Total Debt (Recent Filing)C$423.00K
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Nov 13, 2024EPS Estimate
-$0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding76,986,033
10 Day Avg. Volume145,242
30 Day Avg. Volume180,000
Standard Deviation0.50
R-Squared0.04
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)3.55
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5.22Price Target Upside444.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Oncolytics Biotech News
PremiumCompany Announcements
Oncolytics Biotech Announces Equity Distribution Deal
PremiumCompany Announcements
Oncolytics Biotech Highlights at Growth Conference
PremiumCompany Announcements
Oncolytics Biotech’s Financials Show Asset Decline
PremiumCompany Announcements
Oncolytics Biotech Advances Cancer Trials with Solid Funding
PremiumCompany Announcements
Oncolytics Biotech Announces Q2 Results DiscussionPremiumCompany Announcements
Oncolytics Biotech Advances Towards Drug TrialBulls Say, Bears Say
Bulls Say
Clinical TrialsOncolytics is planning to launch a Phase 2 study with the intent of seeking accelerated approval in HR+/HER2- metastatic breast cancer, following positive feedback from FDA post-Type C meeting.
CollaborationsEntered into collaboration with GCAR for inclusion of pelareorep in an adaptive registration-enabling pancreatic cancer trial in combination with Tecentriq.
Financial PositionThe company expects its current cash position of $24.9M to provide cash runway through 2025 to support the trials being run for pelareorep across various indications, including breast, pancreatic, and anal cancers.
Bears Say
Capital OverhangCapital overhang is expected to maintain pressure on the stock as cash runway is estimated into early 2025, close to breast cancer data.
Clinical Development RiskClinical development risk tied to pelareorep in multiple tumor types poses a significant threat to the stock's performance.
Competitor And Market RisksCompetitor risk in relevant therapeutic areas and capital market and dilution risk could negatively impact the stock's value.
---
Ownership Overview
2.56%
Insiders
0.05% Mutual Funds
0.65% Other Institutional Investors
96.74% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ONCY FAQ
What was Oncolytics Biotech’s price range in the past 12 months?
Oncolytics Biotech lowest stock price was $0.85 and its highest was $2.42 in the past 12 months.
What is Oncolytics Biotech’s market cap?
Currently, no data Available
When is Oncolytics Biotech’s upcoming earnings report date?
Oncolytics Biotech’s upcoming earnings report date is Nov 13, 2024 which is in 74 days.
How were Oncolytics Biotech’s earnings last quarter?
Oncolytics Biotech released its earnings results on Aug 01, 2024. The company reported -$0.074 earnings per share for the quarter, beating the consensus estimate of -$0.076 by $0.001.
Is Oncolytics Biotech overvalued?
According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued.
Does Oncolytics Biotech pay dividends?
Oncolytics Biotech does not currently pay dividends.
What is Oncolytics Biotech’s EPS estimate?
Oncolytics Biotech’s EPS estimate is -$0.08.
How many shares outstanding does Oncolytics Biotech have?
Oncolytics Biotech has 76,986,030 shares outstanding.
What happened to Oncolytics Biotech’s price movement after its last earnings report?
Oncolytics Biotech reported an EPS of -$0.074 in its last earnings report, beating expectations of -$0.076. Following the earnings report the stock price went down -0.971%.
Which hedge fund is a major shareholder of Oncolytics Biotech?
Currently, no hedge funds are holding shares in ONCY
---
Oncolytics Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.22 (444.32% Upside)
$5.22 (444.32% Upside)
Blogger Sentiment
Bearish
ONCY Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.12%
12-Months-Change
Fundamentals
Return on Equity
-137.23%
Trailing 12-Months
Asset Growth
-2.98%
Trailing 12-Months
Company Description
Oncolytics Biotech
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
---
ONCY Earnings Call
Q2 2024
0:00 / 0:00
---
ONCY Stock 12 Month Forecast
Average Price Target
$5.22
▲(444.32% Upside)
Technical Analysis
Best Analysts Covering ONCY
1 Year
1 Year Success Rate
6/22 ratings generated profit
1 Year Average Return
-14.52%
assigned a buy rating 29 days ago
Copying Douglas Miehm's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of -14.52% per trade.
---